Parkinson’s disease medication doesn’t increase risk of cancer

1.4.2015 – The risk of developing prostate cancer in entacapone and levodopa/DDCI users compared to levodopa/DDCI users without entacapone – A nation-wide retrospective register-based study – Pharmacoepidemiological study report published in ENCePP Register of Studies. As a response to FDA commitment, EPID Research performed a study on the association between Parkinson’s disease medication and prostate cancer. Use of entacapone with L- dopa/dopa decarboxylase inhibitor caused no increased risk of prostate cancer incidence or mortality. The report can be found here.